TRINTELLIX

Peak

vortioxetine

NDAORALTABLET
Approved
Sep 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
39

Mechanism of Action

understood, but is thought to be related to its enhancement of serotonergic activity in the CNS through inhibition of the reuptake of serotonin (5-HT). It also has several other activities including 5-HT3 receptor antagonism and 5-HT1A receptor agonism. The contribution of these activities to…

Clinical Trials (5)

NCT07204314Phase 3Recruiting

A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder

Started Oct 2025
180 enrolled
Major Depressive Disorder
NCT05932407N/ACompleted

A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression

Started Jun 2024
147,777 enrolled
Major Depressive Disorder
NCT03580967Phase 4Withdrawn

Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes

Started Jul 2019
0
Type2 DiabetesMajor Depressive Disorder
NCT03779789Phase 4Completed

Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment

Started Feb 2019
362 enrolled
Major Depressive Disorder
NCT02969876Phase 4Terminated

Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine

Started Aug 2017
2 enrolled
Depressive DisorderMajor DepressionDepression+1 more

Loss of Exclusivity

LOE Date
Sep 21, 2032
79 months away
Patent Expiry
Sep 21, 2032
Exclusivity Expiry
Feb 23, 2027

Patent Records (5)

Patent #ExpiryTypeUse Code
7144884
Jun 17, 2026
SubstanceProduct
U-1439
7144884*PED
Dec 17, 2026
11458134
Jun 15, 2027
Product
U-3463
8969355
Jun 15, 2027
U-1668
9125908
Jun 15, 2027
U-2309